PET-o-RAMA, page-135

First 135 Last

Share
Profile

Follow
SSPPMM

1,125 Posts.

331

29/01/20

19:20

Post #: 42629320
Share

Originally posted by Mickem: ↑

Hi SSPPMM
not following your post are you talking about 2019 sales ? and at the $3k per tons how do you get $32m to $35m ? . 4k tons would be 12m and 5k tons $15m at the $3000 per ton . we are starting at $10.2m for the first half . as i have said before I think the figure is more than $3000 per ton. the tonage for the second half hard to work out at this stage because figure for Xingyun has been changing, 3500 then 3300 and over 3000 tons for this lake are ones i have seen but these are for tons to the end of the year but some of these would have been counted in the first half . Xingyun for the second half i'm guessing 2700 tons (Using the lower 3000 figure and allowing 300 tons in the first half), we know 400 tons to florida, i believe 500 tons went into wuhan (east lake) so that gives me 3600 tons. i would also image usa took more than the 400 for other little treatments , europe and brazil should of had some. canal might of had some as well so should hopefully be the 4000 tons , usa tons was at $3250 per ton, think this will be $3000 for product and $250 shipping. tons into china should be high price as we do the application . i would think phoslock sales for 4000 tons will come in at $14m plus we should have about $4m in wetlands so about $28m is my best guest.
lots of assumptions in my working so like the other Mick i'm nervous. although my plans are long term i still look short term as well. this quarterly so important to the long term sp. although i think sp will increase this year as work and money flows in the question will be after friday we will be looking at a sp in the 60s or 90s as a starting point
one thing in the back of my mind is the first half seemed slow compared to the second half. first half didn't have 500 for east lake , 400 florida or all the extra tonage that has gone into Xingyun , wetlands work should be higher in the second half as well . so if we done $10m first half with all the extra active in the second half you would think forecast should be fine.

we will know soon enough and then we all can start inturprating the meanings in the report again

thanks
Mickem

Expand

Hi Mickem!!

From the 16 Oct update:

"Financial Commentary

Receipts from customers were $4.6m for the September quarter, making a total of $23.3m for the first nine months.........."

$23.3 mil (unless I've misinterpreted it) plus 4000 tonnes at $3000 per tonne = Approx $35 million

Cheers!!!

PET Price at posting: 76.5¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 2 more messages in this thread...

First 135 Last

Add PET (ASX) to my watchlist

(20min delay)
Last 2.5¢		Change 0.000(0.00%)		Mkt cap ! $15.60M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

PET-o-RAMA, page-135

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Featured News

PET-o-RAMA, page-135

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Featured News